{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:51:32Z","timestamp":1791820292231,"version":"4.3.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"GentiBio Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Allogeneic cell therapies offer a scalable and off-the-shelf alternative to the autologous approach, but immune rejection, particularly by natural killer (NK) cells following human leukocyte antigen (HLA) ablation, remains a major barrier to their persistence. Here, we report an improved synthetic NKG2A engager to selectively inhibit NKG2A\u207a NK cells while avoiding activation of NKG2C\u207a subsets, thereby overcoming a key limitation of the natural ligand HLA-E. Engineered regulatory T cells (EngTregs) lacking HLA and expressing the engager were protected from in vitro NK cell-mediated cytotoxicity more effectively than previously reported NK inhibitory strategies. In humanized mouse models, EngTregs persisted for up to 12 weeks, whereas unprotected cells were rapidly rejected. Incorporation of the engager into a clinically compatible dual-AAV EngTregs preserved Treg identity and function while conferring resistance to immune rejection. Together, these findings establish the improved NKG2A engager as an effective synthetic immune-evasion strategy and provide a clinically translatable approach to enable durable persistence of off-the-shelf EngTreg therapies.<\/jats:p>","DOI":"10.1038\/s44321-026-00507-4","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T09:04:06Z","timestamp":1787821446000},"page":"3939-3960","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A synthetic NKG2A engager enables long-term persistence of HLA-deficient allogeneic engineered Tregs"],"prefix":"10.1038","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2968-7187","authenticated-orcid":false,"given":"Tingxi","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9164-5159","authenticated-orcid":false,"given":"Kaya R","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7280-179X","authenticated-orcid":false,"given":"Maegan E","family":"Hoover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan W","family":"Zammit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer Y","family":"Yam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Hussell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payam","family":"Zarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Sassone-Corsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gene I","family":"Uenishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wickham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"507_CR1","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3390\/v15020365","volume":"15","author":"SA Abeynaike","year":"2023","unstructured":"Abeynaike SA, Huynh TR, Mehmood A, Kim T, Frank K, Gao K, Zalfa C, Gandarilla A, Shultz L, Paust S (2023) Human hematopoietic stem cell engrafted IL-15 transgenic NSG mice support robust NK cell responses and sustained HIV-1infection. Viruses 15:365","journal-title":"Viruses"},{"key":"507_CR2","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.immuni.2006.06.013","volume":"25","author":"N Anfossi","year":"2006","unstructured":"Anfossi N, Andre P, Guia S, Falk CS, Roetynck S, Stewart CA, Breso V, Frassati C, Reviron D, Middleton D et al (2006) Human NK cell education by inhibitory receptors for MHC class I. Immunity 25:331\u2013342","journal-title":"Immunity"},{"key":"507_CR3","doi-asserted-by":"publisher","first-page":"e22476","DOI":"10.1096\/fj.202200045R","volume":"36","author":"KE Aryee","year":"2022","unstructured":"Aryee KE, Burzenski LM, Yao LC, Keck JG, Greiner DL, Shultz LD, Brehm MA (2022) Enhanced development of functional human NK cells in NOD-scid-IL2rg(null) mice expressing human IL15. FASEB J 36:e22476","journal-title":"FASEB J"},{"key":"507_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.chembiol.2005.10.017","volume":"13","author":"JH Bayle","year":"2006","unstructured":"Bayle JH, Grimley JS, Stankunas K, Gestwicki JE, Wandless TJ, Crabtree GR (2006) Rapamycin analogs with differential binding specificity permit orthogonal control of protein activity. Chem Biol 13:99\u2013107","journal-title":"Chem Biol"},{"key":"507_CR5","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/35869","volume":"391","author":"VM Braud","year":"1998","unstructured":"Braud VM, Allan DS, O\u2019Callaghan CA, Soderstrom K, D\u2019Andrea A, Ogg GS, Lazetic S, Young NT, Bell JI, Phillips JH et al (1998) HLA-E binds to natural killer cell receptors CD94\/NKG2A, B and C. Nature 391:795\u2013799","journal-title":"Nature"},{"key":"507_CR6","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1056\/NEJMoa2503822","volume":"393","author":"PO Carlsson","year":"2025","unstructured":"Carlsson PO, Hu X, Scholz H, Ingvast S, Lundgren T, Scholz T, Eriksson O, Liss P, Yu D, Deuse T et al (2025) Survival of transplanted allogeneic beta cells with no immunosuppression. N Engl J Med 393:887\u2013894","journal-title":"N Engl J Med"},{"key":"507_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111423","volume":"40","author":"R Chimienti","year":"2022","unstructured":"Chimienti R, Baccega T, Torchio S, Manenti F, Pellegrini S, Cospito A, Amabile A, Lombardo MT, Monti P, Sordi V et al (2022) Engineering of immune checkpoints B7-H3 and CD155 enhances immune compatibility of MHC-I(-\/-) iPSCs for beta cell replacement. Cell Rep 40:111423","journal-title":"Cell Rep"},{"key":"507_CR8","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41577-024-01035-3","volume":"24","author":"JB Chung","year":"2024","unstructured":"Chung JB, Brudno JN, Borie D, Kochenderfer JN (2024) Chimeric antigen receptor T cell therapy for autoimmune disease. Nat Rev Immunol 24:830\u2013845","journal-title":"Nat Rev Immunol"},{"key":"507_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/CJI.0000000000000552","volume":"48","author":"LJ Coholan","year":"2025","unstructured":"Coholan LJ, Karaca C, Musenge FM, White ML, Camblin AJ, Leboeuf D, Maldini CR (2025) Combined CLEC2d expression and CD58 loss mitigate rejection of allogeneic T cells. J Immunother 48:127\u2013137","journal-title":"J Immunother"},{"key":"507_CR10","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1016\/j.ymthe.2023.04.021","volume":"31","author":"PJ Cook","year":"2023","unstructured":"Cook PJ, Yang SJ, Uenishi GI, Grimm A, West SE, Wang LJ, Jacobs C, Repele A, Drow T, Boukhris A et al (2023) A chemically inducible IL-2 receptor signaling complex allows for effective in vitro and in vivo selection of engineered CD4+ T cells. Mol Ther 31:2472\u20132488","journal-title":"Mol Ther"},{"key":"507_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/imr.12520","volume":"276","author":"M Das","year":"2017","unstructured":"Das M, Zhu C, Kuchroo VK (2017) Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev 276:97\u2013111","journal-title":"Immunol Rev"},{"key":"507_CR12","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1158\/2326-6066.CIR-23-0679","volume":"12","author":"E Degagne","year":"2024","unstructured":"Degagne E, Donohoue PD, Roy S, Scherer J, Fowler TW, Davis RT, Reyes GA, Kwong G, Stanaway M, Larroca Vicena V et al (2024) High-specificity CRISPR-mediated genome engineering in anti-BCMA allogeneic CAR T cells suppresses allograft rejection in preclinical models. Cancer Immunol Res 12:462\u2013477","journal-title":"Cancer Immunol Res"},{"key":"507_CR13","doi-asserted-by":"publisher","first-page":"e20200839","DOI":"10.1084\/jem.20200839","volume":"218","author":"T Deuse","year":"2021","unstructured":"Deuse T, Hu X, Agbor-Enoh S, Jang MK, Alawi M, Saygi C, Gravina A, Tediashvili G, Nguyen VQ, Liu Y et al (2021) The SIRPalpha-CD47 immune checkpoint in NK cells. J Exp Med 218:e20200839","journal-title":"J Exp Med"},{"key":"507_CR14","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/s41587-019-0016-3","volume":"37","author":"T Deuse","year":"2019","unstructured":"Deuse T, Hu X, Gravina A, Wang D, Tediashvili G, De C, Thayer WO, Wahl A, Garcia JV, Reichenspurner H et al (2019) Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients. Nat Biotechnol 37:252\u2013258","journal-title":"Nat Biotechnol"},{"key":"507_CR15","doi-asserted-by":"publisher","first-page":"6010","DOI":"10.4049\/jimmunol.181.9.6010","volume":"181","author":"C Fauriat","year":"2008","unstructured":"Fauriat C, Andersson S, Bjorklund AT, Carlsten M, Schaffer M, Bjorkstrom NK, Baumann BC, Michaelsson J, Ljunggren HG, Malmberg KJ (2008) Estimation of the size of the alloreactive NK cell repertoire: studies in individuals homozygous for the group A KIR haplotype. J Immunol 181:6010\u20136019","journal-title":"J Immunol"},{"key":"507_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1647433","volume":"16","author":"G Golinelli","year":"2025","unstructured":"Golinelli G, Scholler J, Roussel-Gervais A, Sakic A, Ilmjarv S, Song D, Gabunia K, Ji M, Fan TJ, Gupta A et al (2025) Multiplex engineering using microRNA-mediated gene silencing in CAR T cells. Front Immunol 16:1647433","journal-title":"Front Immunol"},{"key":"507_CR17","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nbt.3860","volume":"35","author":"GG Gornalusse","year":"2017","unstructured":"Gornalusse GG, Hirata RK, Funk SE, Riolobos L, Lopes VS, Manske G, Prunkard D, Colunga AG, Hanafi LA, Clegg DO et al (2017) HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells. Nat Biotechnol 35:765\u2013772","journal-title":"Nat Biotechnol"},{"key":"507_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0952-7915(96)80108-7","volume":"8","author":"E Goulmy","year":"1996","unstructured":"Goulmy E (1996) Human minor histocompatibility antigens. Curr Opin Immunol 8:75\u201381","journal-title":"Curr Opin Immunol"},{"key":"507_CR19","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1056\/NEJMsa1311707","volume":"371","author":"L Gragert","year":"2014","unstructured":"Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R, Hartzman R, Rizzo JD, Horowitz M, Confer D et al (2014) HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med 371:339\u2013348","journal-title":"N Engl J Med"},{"key":"507_CR20","doi-asserted-by":"publisher","first-page":"e008417","DOI":"10.1136\/jitc-2023-008417","volume":"12","author":"K Grauwet","year":"2024","unstructured":"Grauwet K, Berger T, Kann MC, Silva H, Larson R, Leick MB, Bailey SR, Bouffard AA, Millar D, Gallagher K et al (2024) Stealth transgenes enable CAR-T cells to evade host immune responses. J Immunother Cancer 12:e008417","journal-title":"J Immunother Cancer"},{"key":"507_CR21","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/j.stem.2023.10.003","volume":"30","author":"A Gravina","year":"2023","unstructured":"Gravina A, Tediashvili G, Zheng Y, Iwabuchi KA, Peyrot SM, Roodsari SZ, Gargiulo L, Kaneko S, Osawa M, Schrepfer S et al (2023) Synthetic immune checkpoint engagers protect HLA-deficient iPSCs and derivatives from innate immune cell cytotoxicity. Cell Stem Cell 30:1538\u20131548 e1534","journal-title":"Cell Stem Cell"},{"key":"507_CR22","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.stem.2024.06.011","volume":"31","author":"Q Hammer","year":"2024","unstructured":"Hammer Q, Perica K, Mbofung RM, van Ooijen H, Martin KE, Momayyezi P, Varady E, Pan Y, Jelcic M, Groff B et al (2024) Genetic ablation of adhesion ligands mitigates rejection of allogeneic cellular immunotherapies. Cell Stem Cell 31:1376\u20131386 e1378","journal-title":"Cell Stem Cell"},{"key":"507_CR23","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jcyt.2019.01.003","volume":"21","author":"RP Harrison","year":"2019","unstructured":"Harrison RP, Zylberberg E, Ellison S, Levine BL (2019) Chimeric antigen receptor-T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods. Cytotherapy 21:224\u2013233","journal-title":"Cytotherapy"},{"key":"507_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.559576","volume":"11","author":"AJ Highton","year":"2020","unstructured":"Highton AJ, Diercks BP, Mockl F, Martrus G, Sauter J, Schmidt AH, Bunders MJ, Korner C, Guse AH, Altfeld M (2020) High metabolic function and resilience of NKG2A-educated NK cells. Front Immunol 11:559576","journal-title":"Front Immunol"},{"key":"507_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-18394-z","volume":"15","author":"S Hiura","year":"2025","unstructured":"Hiura S, Kuwasaki Y, Nishikawa Y, Kimura T, Yoshida S, Nakayama M, Makino T, Ueno S (2025) Selective agonists of KIR and NKG2A to evade missing self response of natural killer cells. Sci Rep 15:33550","journal-title":"Sci Rep"},{"key":"507_CR26","doi-asserted-by":"publisher","first-page":"eaay6422","DOI":"10.1126\/scitranslmed.aay6422","volume":"12","author":"Y Honaker","year":"2020","unstructured":"Honaker Y, Hubbard N, Xiang Y, Fisher L, Hagin D, Sommer K, Song Y, Yang SJ, Lopez C, Tappen T et al (2020) Gene editing to induce FOXP3 expression in human CD4(+) T cells leads to a stable regulatory phenotype and function. Sci Transl Med 12:eaay6422","journal-title":"Sci Transl Med"},{"key":"507_CR27","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41587-023-01784-x","volume":"42","author":"X Hu","year":"2024","unstructured":"Hu X, White K, Olroyd AG, DeJesus R, Dominguez AA, Dowdle WE, Friera AM, Young C, Wells F, Chu EY et al (2024) Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus macaques. Nat Biotechnol 42:413\u2013423","journal-title":"Nat Biotechnol"},{"key":"507_CR28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00467-008-1020-x","volume":"25","author":"E Ingulli","year":"2010","unstructured":"Ingulli E (2010) Mechanism of cellular rejection in transplantation. Pediatr Nephrol 25:61\u201374","journal-title":"Pediatr Nephrol"},{"key":"507_CR29","doi-asserted-by":"publisher","first-page":"23068","DOI":"10.1074\/jbc.M112.357673","volume":"287","author":"M Irving","year":"2012","unstructured":"Irving M, Zoete V, Hebeisen M, Schmid D, Baumgartner P, Guillaume P, Romero P, Speiser D, Luescher I, Rufer N et al (2012) Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. J Biol Chem 287:23068\u201323078","journal-title":"J Biol Chem"},{"key":"507_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30896-2","volume":"13","author":"S Jo","year":"2022","unstructured":"Jo S, Das S, Williams A, Chretien AS, Pagliardini T, Le Roy A, Fernandez JP, Le Clerre D, Jahangiri B, Chion-Sotinel I et al (2022) Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing. Nat Commun 13:3453","journal-title":"Nat Commun"},{"key":"507_CR31","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1158\/2326-6066.CIR-18-0508","volume":"8","author":"Y Kagoya","year":"2020","unstructured":"Kagoya Y, Guo T, Yeung B, Saso K, Anczurowski M, Wang CH, Murata K, Sugata K, Saijo H, Matsunaga Y et al (2020) Genetic ablation of HLA class I, class II, and the T-cell receptor enables allogeneic T cells to be used for adoptive T-cell therapy. Cancer Immunol Res 8:926\u2013936","journal-title":"Cancer Immunol Res"},{"key":"507_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17442-7","volume":"7","author":"I Katano","year":"2017","unstructured":"Katano I, Nishime C, Ito R, Kamisako T, Mizusawa T, Ka Y, Ogura T, Suemizu H, Kawakami Y, Ito M et al (2017) Long-term maintenance of peripheral blood derived human NK cells in a novel human IL-15- transgenic NOG mouse. Sci Rep 7:17230","journal-title":"Sci Rep"},{"key":"507_CR33","doi-asserted-by":"publisher","first-page":"734","DOI":"10.3389\/fimmu.2019.00734","volume":"10","author":"JB Le Luduec","year":"2019","unstructured":"Le Luduec JB, Boudreau JE, Freiberg JC, Hsu KC (2019) Novel approach to cell surface discrimination between KIR2DL1 subtypes and KIR2DS1 identifies hierarchies in nk repertoire, education, and tolerance. Front Immunol 10:734","journal-title":"Front Immunol"},{"key":"507_CR34","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.immuni.2020.04.011","volume":"52","author":"MEW Logtenberg","year":"2020","unstructured":"Logtenberg MEW, Scheeren FA, Schumacher TN (2020) The CD47-SIRPalpha immune checkpoint. Immunity 52:742\u2013752","journal-title":"Immunity"},{"key":"507_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1032403","volume":"13","author":"R Mao","year":"2022","unstructured":"Mao R, Kong W, He Y (2022) The affinity of antigen-binding domain on the antitumor efficacy of CAR T cells: moderate is better. Front Immunol 13:1032403","journal-title":"Front Immunol"},{"key":"507_CR36","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41577-024-01022-8","volume":"24","author":"KE Martin","year":"2024","unstructured":"Martin KE, Hammer Q, Perica K, Sadelain M, Malmberg KJ (2024) Engineering immune-evasive allogeneic cellular immunotherapies. Nat Rev Immunol 24:680\u2013693","journal-title":"Nat Rev Immunol"},{"key":"507_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-64945-3","volume":"16","author":"O McCallion","year":"2025","unstructured":"McCallion O, Du W, Glaser V, Milward K, Short S, Bilici M, Cross A, Stark H, Franke C, Kath J et al (2025) HLA matching or CRISPR editing of HLA class I\/II enables engraftment and effective function of allogeneic human regulatory T cell therapy in a humanized mouse transplantation model. Nat Commun 16:9090","journal-title":"Nat Commun"},{"key":"507_CR38","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/tan.14640","volume":"100","author":"R Meazza","year":"2022","unstructured":"Meazza R, Falco M, Canevali P, Loiacono F, Colomar-Carando N, Muntasell A, Rea A, Mingari MC, Locatelli F, Moretta L et al (2022) Characterization of KIR(+) NK cell subsets with a monoclonal antibody selectively recognizing KIR2DL1 and blocking the specific interaction with HLA-C. HLA 100:119\u2013132","journal-title":"HLA"},{"key":"507_CR39","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41587-020-0601-5","volume":"39","author":"F Mo","year":"2021","unstructured":"Mo F, Watanabe N, McKenna MK, Hicks MJ, Srinivasan M, Gomes-Silva D, Atilla E, Smith T, Ataca Atilla P, Ma R et al (2021) Engineered off-the-shelf therapeutic T cells resist host immune rejection. Nat Biotechnol 39:56\u201363","journal-title":"Nat Biotechnol"},{"key":"507_CR40","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","volume":"33","author":"KK Patel","year":"2025","unstructured":"Patel KK, Tariveranmoshabad M, Kadu S, Shobaki N, June C (2025) From concept to cure: the evolution of CAR-T cell therapy. Mol Ther 33:2123\u20132140","journal-title":"Mol Ther"},{"key":"507_CR41","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/s41586-025-08657-0","volume":"640","author":"K Perica","year":"2025","unstructured":"Perica K, Kotchetkov IS, Mansilla-Soto J, Ehrich F, Herrera K, Shi Y, Dobrin A, Gonen M, Sadelain M (2025) HIV immune evasin Nef enhances allogeneic CAR T cell potency. Nature 640:793\u2013801","journal-title":"Nature"},{"key":"507_CR42","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.stemcr.2023.12.003","volume":"19","author":"HA Pizzato","year":"2024","unstructured":"Pizzato HA, Alonso-Guallart P, Woods J, Connelly JP, Fehniger TA, Atkinson JP, Pruett-Miller SM, Monsma JrFJ, Bhattacharya D (2024) Engineering human pluripotent stem cell lines to evade xenogeneic transplantation barriers. Stem Cell Rep 19:299\u2013313","journal-title":"Stem Cell Rep"},{"key":"507_CR43","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/bmt.2017.81","volume":"52","author":"S Rathmann","year":"2017","unstructured":"Rathmann S, Keck C, Kreutz C, Weit N, Muller M, Timmer J, Glatzel S, Follo M, Malkovsky M, Werner M et al (2017) Partial break in tolerance of NKG2A(-)\/LIR-1(-) single KIR(+) NK cells early in the course of HLA-matched, KIR-mismatched hematopoietic cell transplantation. Bone Marrow Transplant 52:1144\u20131155","journal-title":"Bone Marrow Transplant"},{"key":"507_CR44","doi-asserted-by":"crossref","unstructured":"Richard Ruiz ADK (2015) Long-term toxicity of immunosuppressive therapy. Transplantation of the Liver:1354\u20131363","DOI":"10.1016\/B978-1-4557-0268-8.00097-X"},{"key":"507_CR45","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/eji.201545757","volume":"46","author":"MJ Sim","year":"2016","unstructured":"Sim MJ, Stowell J, Sergeant R, Altmann DM, Long EO, Boyton RJ (2016) KIR2DL3 and KIR2DL1 show similar impact on licensing of human NK cells. Eur J Immunol 46:185\u2013191","journal-title":"Eur J Immunol"},{"key":"507_CR46","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1182\/blood-2011-08-372425","volume":"119","author":"VR Simhadri","year":"2012","unstructured":"Simhadri VR, Andersen JF, Calvo E, Choi SC, Coligan JE, Borrego F (2012) Human CD300a binds to phosphatidylethanolamine and phosphatidylserine, and modulates the phagocytosis of dead cells. Blood 119:2799\u20132809","journal-title":"Blood"},{"key":"507_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103327","volume":"149","author":"R Tewari","year":"2024","unstructured":"Tewari R, Yang SJ, McClain ED, Hu A, Mortensen E, DeSchmidt A, Chen J, Kancharla A, Singh AK, James EA et al (2024) Identification of a novel PDC-E2 epitope in primary biliary cholangitis: application for engineered Treg therapy. J Autoimmun 149:103327","journal-title":"J Autoimmun"},{"key":"507_CR48","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/mt.2016.106","volume":"24","author":"H Torikai","year":"2016","unstructured":"Torikai H, Cooper LJ (2016) Translational implications for off-the-shelf immune cells expressing chimeric antigen receptors. Mol Ther 24:1178\u20131186","journal-title":"Mol Ther"},{"key":"507_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2025.101561","volume":"33","author":"SK Tripathi","year":"2025","unstructured":"Tripathi SK, Grimm A, Dahl NP, Honaker Y, Knebusch P, Chen Y, Cook PJ, Rawlings DJ (2025) HLA-A2 CAR\/IL-2-CISC engineered Treg display robust in vitro and in vivo antigen-specific regulatory function. Mol Ther Methods Clin Dev 33:101561","journal-title":"Mol Ther Methods Clin Dev"},{"key":"507_CR50","doi-asserted-by":"publisher","first-page":"e171844","DOI":"10.1172\/jci.insight.171844","volume":"9","author":"GI Uenishi","year":"2024","unstructured":"Uenishi GI, Repic M, Yam JY, Landuyt A, Saikumar-Lakshmi P, Guo T, Zarin P, Sassone-Corsi M, Chicoine A, Kellogg H et al (2024) GNTI-122: an autologous antigen-specific engineered Treg cell therapy for type 1 diabetes. JCI Insight 9:e171844","journal-title":"JCI Insight"},{"key":"507_CR51","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s40425-019-0761-3","volume":"7","author":"T van Hall","year":"2019","unstructured":"van Hall T, Andre P, Horowitz A, Ruan DF, Borst L, Zerbib R, Narni-Mancinelli E, van der Burg SH, Vivier E (2019) Monalizumab: inhibiting the novel immune checkpoint NKG2A. J Immunother Cancer 7:263","journal-title":"J Immunother Cancer"},{"key":"507_CR52","doi-asserted-by":"publisher","first-page":"17675","DOI":"10.18632\/oncotarget.24832","volume":"9","author":"N Vey","year":"2018","unstructured":"Vey N, Karlin L, Sadot-Lebouvier S, Broussais F, Berton-Rigaud D, Rey J, Charbonnier A, Marie D, Andre P, Paturel C et al (2018) A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies. Oncotarget 9:17675\u201317688","journal-title":"Oncotarget"},{"key":"507_CR53","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41551-021-00730-z","volume":"5","author":"B Wang","year":"2021","unstructured":"Wang B, Iriguchi S, Waseda M, Ueda N, Ueda T, Xu H, Minagawa A, Ishikawa A, Yano H, Ishi T et al (2021) Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells. Nat Biomed Eng 5:429\u2013440","journal-title":"Nat Biomed Eng"},{"key":"507_CR54","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1097\/TP.0000000000001115","volume":"100","author":"RC Williams","year":"2016","unstructured":"Williams RC, Opelz G, McGarvey CJ, Weil EJ, Chakkera HA (2016) The risk of transplant failure with HLA mismatch in first adult kidney allografts from deceased donors. Transplantation 100:1094\u20131102","journal-title":"Transplantation"},{"key":"507_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/TP.0b013e31823cab44","volume":"93","author":"KJ Wood","year":"2012","unstructured":"Wood KJ, Goto R (2012) Mechanisms of rejection: current perspectives. Transplantation 93:1\u201310","journal-title":"Transplantation"},{"key":"507_CR56","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn1716","volume":"14","author":"SJ Yang","year":"2022","unstructured":"Yang SJ, Singh AK, Drow T, Tappen T, Honaker Y, Barahmand-Pour-Whitman F, Linsley PS, Cerosaletti K, Mauk K, Xiang Y et al (2022) Pancreatic islet-specific engineered T(regs) exhibit robust antigen-specific and bystander immune suppression in type 1 diabetes models. Sci Transl Med 14:eabn1716","journal-title":"Sci Transl Med"},{"key":"507_CR57","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1182\/blood-2008-03-143727","volume":"112","author":"M Yawata","year":"2008","unstructured":"Yawata M, Yawata N, Draghi M, Partheniou F, Little AM, Parham P (2008) MHC class I-specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response. Blood 112:2369\u20132380","journal-title":"Blood"},{"key":"507_CR58","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1182\/bloodadvances.2024013436","volume":"9","author":"SQ Zhang","year":"2025","unstructured":"Zhang SQ, Thomas F, Fang J, Austgen K, Cowan C, Welstead GG (2025) Universal protection of allogeneic T-cell therapies from natural killer cells via CD300a agonism. Blood Adv 9:254\u2013264","journal-title":"Blood Adv"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-026-00507-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44321-026-00507-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-026-00507-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:41:56Z","timestamp":1791819716000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44321-026-00507-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":58,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,12]]}},"alternative-id":["507"],"URL":"https:\/\/doi.org\/10.1038\/s44321-026-00507-4","relation":{},"ISSN":["1757-4684"],"issn-type":[{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"assertion":[{"value":"3 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors are present or past employees of GentiBio, Inc. GentiBio has filed a patent application related to this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interest statement"}}]}}